BioCure, Inc.
https://www.biocure.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioCure, Inc.
Biocompatibles: Crossing Over to the Convergence Side in Cancer and Stroke
Biocompatibles has re-invented itself a third time, exiting traditional device markets for riskier drug-device convergence plays in oncology and stroke, clinical areas dominated by drug therapy. This move has caught drug companies' attention clinically, but will Big Pharma validate Biocompatibles' strategy commercially?
Biocompatibles: The Perils of Re-Inventing a Public Company
The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears and apply their original or another technooloogy to a different clinical need. Indeed, Biocompatibles is now workiing on its third primary therapeutic areas--cancer--having previously sold off its first two businesses, in ophthalmology and then, convinced it was too far behind in drug-eluting stents, cardiovascular. This new growth area is being driven by the company's general expertise in polymer technology and drug delivery.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- BioCure Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice